Keymed Biosciences Inc. released its Monthly Return for the period ended 31 May 2026, confirming that equity structure and public float remained stable throughout the month.

Authorised Share Capital • The company’s authorised share base stayed at 500.00 million ordinary shares, each with a par value of USD 0.0001, representing total authorised capital of USD 50,000. No increase or decrease was recorded during May.

Issued Shares and Treasury Position • Issued shares at month-end were unchanged at 298.74 million. • The firm held no treasury shares, leaving total issued share count also at 298.74 million.

Public Float Compliance • Keymed Biosciences affirmed compliance with the Main Board’s minimum 25 % public float requirement as of 31 May 2026.

Capital-Related Instruments • The filing recorded no activity in share options, warrants, convertible securities or other share-issuance agreements during the month.

Management Sign-off • The return was submitted on 02 June 2026 by Executive Director Dr. Bo Chen.